By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Gonadotropins > Bravelle > Urofollitropin Dosage
Gonadotropins
https://themeditary.com/dosage-information/urofollitropin-dosage-1905.html

Urofollitropin Dosage

Drug Detail:Bravelle (Urofollitropin [ ure-oh-fol-i-troe-pin ])

Drug Class: Gonadotropins

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Follicle Stimulation

Ovulation induction:
Initial dose: 150 international units per day for 5 days, subcutaneously (SC) or intramuscularly (IM)
Maximum dose: 450 international units per day
Duration of therapy: 12 days

Comments:

  • When pre-ovulatory conditions are reached, administer human chorionic gonadotropin (hCG) to induce final oocyte maturation and ovulation.
  • Withhold hCG when monitoring suggests an increased risk of ovarian hyperstimulation syndrome (OHSS) on the last day of therapy.
  • Encourage daily intercourse, beginning on the day prior to hCG and until ovulation becomes apparent.
  • Discourage intercourse when the risk for OHSS is increased.

Assisted reproduction:
Initial dose: 225 international units per day for 5 days, subcutaneously
  • If given with menotropin, the total combined dose should not exceed 225 international units (150 international units urofollitropin and 75 international units menotropin, or 75 international units urofollitropin and 150 international units menotropin).
Maximum dose: 450 international units per day
  • If given with menotropin, the total combined dose of urofollitropin and menotropin should not exceed 450 international units per day.
Duration of therapy: 12 days

Comments:
  • Beginning on cycle day 2 or 3, administer daily until sufficient follicular development is attained, as determined by ultrasound and measurement of serum estradiol levels.
  • Continue treatment until adequate follicular development is evident, and then administer hCG.
  • Withhold hCG where monitoring suggests an increased risk of OHSS on the last day of therapy.

Uses:
  • Induction of ovulation in women who have previously received pituitary suppression - intramuscular and subcutaneous administration.
  • Development of multiple follicles as part of an Assisted Reproductive Technology (ART) cycle in ovulatory women who have previously received pituitary suppression.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Ovulation Induction

  • The dosing scheme is stepwise and is individualized for each woman.
  • For women who have received GnRH agonist or pituitary suppression, a starting dose is administered subcutaneously or intramuscularly for 5 days in the first cycle of treatment.
  • In subsequent cycles the starting dose and dosage adjustments should be determined based on ovarian response.
  • Dose adjustments based on clinical monitoring (including serum estradiol levels and vaginal ultrasound results) should be used to prevent multiple follicular growth and cycle cancellation.
  • Do not adjust dose more frequently than once every 2 days and do not exceed 150 international units per adjustment.
  • Use the lowest dose that will achieve desired results.
  • In general, do not exceed 12 days of treatment.

Assisted Reproductive Technology (ART)
  • The recommended dosing scheme for patients undergoing IVF follows a stepwise approach and is individualized for each woman.
  • Adjust the dose after 5 days based on ovarian response, as determined by ultrasound evaluation of follicular growth and serum estradiol levels.
  • Do not adjust dose more frequently than once every 2 days and do not exceed 150 international units per adjustment.
  • In most cases, therapy should not exceed 12 days.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Inspect for particulate matter and discoloration prior to administration.
  • Alternate injection site daily.
  • Administer subcutaneously in the abdomen or intramuscularly.
  • If using intramuscularly, a healthcare provider should administer the product.

Storage requirements:
  • Store refrigerated or at room temperature; protect from light.
  • Use immediately after reconstitution. Discard unused material.

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

Patient advice:
  • Prior to beginning therapy, inform women about the time commitment and monitoring procedures necessary for treatment.
  • Instruct women on the correct usage and dosing.
  • If a dose is missed, the next dose should not be doubled. The patient should call her healthcare provider for further dosing instructions.
  • Caution women not to change the dosage or the schedule of administration unless told to do so by her healthcare provider.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by